Please login to the form below
Abivax
This page shows the latest Abivax news and features for those working in and with pharma, biotech and healthcare.
Mesoblast expands compassionate use COVID-19 programme
A host of candidates are being investigated to regulate the overactive inflammatory side effects associated with some cases of COVID-19, including Abivax’s experimental anti-inflammatory med ABX464. ... Last week, Abivax initiated a phase 2b/3 study
Latest news
-
Abivax doses first patient in phase 2b/3 COVID-19 clinical trial
Study will evaluate experimental anti-inflammatory drug. French biotech company Abivax has treated the first patient in a phase 2b/3 study of its experimental anti-inflammatory drug ABX464 in ... Currently, Abivax has received approval for studies in
-
Trial data suggest Abivax’ drug may clear latent HIV
The drug reduced HIV DNA in cells over 28 days. French biotech Abivax has new data for its HIV drug candidate ABX464 that suggest it may suppress latent HIV in reservoirs – ... Those anti-inflammatory properties have encouraged Abivax to carry out a
-
J&J buys firm seeking hepatitis B cure
therapeutic vaccine developer Abivax are trying to change.
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
The race for a HIV ‘cure’
Another company working on a similar candidate is French biotech Abivax.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Communique - Communiqué Awards
- How will the events and exhibitions industry change post-Coronavirus?
- Sinovac reveals positive preliminary data for COVID-19 vaccine
- FDA approves Roche’s Actemra COVID-19 trial
- Abivax doses first patient in phase 2b/3 COVID-19 clinical trial
- Finalists 2020 - Communiqué Awards
- OPEN Health scoops up Medical Affairs Agency Award at Communiqué 2020
- GSK signs deal with Medicargo for COVID-19 vaccine
- Moderna clashes with US scientists over pivotal COVID-19 vaccine trials
- EU gives AZ’s Lynparza green light for BRCA-mutated pancreatic cancer
- A snapshot of… Exscientia
- McCann Health London bolsters creative leadership team
PMHub
Fishawack Group of Companies
The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...
Latest intelligence
- A snapshot of… Exscientia
- ...
- Patients are ready for virtual clinical trials, are you?
- Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
- Keep your audiences close
- How getting up close and personal with target audiences can fuel creativity...
Quick links
Infographics
